WuXi PharmaTech Building CAR T Facility in Philadelphia

WuXi PharmaTech, a China-US CRO, will build a new facility on its Philadelphia campus to manufacture viral vector cell therapy products, such as chimeric antigen receptor T cell (CAR T cell) therapies. The 145,000-square-foot cGMP plant is in addition to a 45,000 square foot cell therapy manufacturing facility WuXi announced one year ago, which is now nearing completion. WuXi said the cost for the two Philadelphia manufacturing plants totals $40 million. In China, WuXi has two additional building projects underway: a small-molecule plant in Changzhou and a commercial-scale biologics plant in Wuxi city at a total cost of $300 million. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.